PARP14 promotes the proliferation and gemcitabine chemoresistance of pancreatic cancer cells through activation of NF-κB pathway.

Pancreatic cancer (PC) is the most fatal gastrointestinal malignancy in the world, with a 5-year relative survival of only 8%. Poly(ADP-ribose) polymerase a member of the subfamily proteins, has been reported to participate in various biologic and pathologic processes in multiple cancers. The roles and underlying molecular mechanisms of in PC carcinogenesis, however, remain to be elucidated. In this study, we for the first time discovered that Pduanyu3714 was highly expressed in human primary PC specimens and significantly correlated with poor patient prognosis. Using loss-of-function studies in vitro and in vivo, we showed that the knockdown of Pduanyu3714 led to enhanced apoptosis, repressed proliferation, and gemcitabine (GEM) resistance of PC cells. Further investigations revealed that Pduanyu3714 was significantly overexpressed in GEM-resistant PC cells (SW1990/GZ). And silencing of Pduanyu3714 significantly reversed the GEM resistance of SW1990/GZ cells. To the mechanism, Pduanyu3714 could stimulate PC progression by the activation of nuclear factor-κB (NF-κB) signaling pathway. And inhibition of NF-κB signal could significantly reverse triggered PC carcinogenesis. In conclusion, Pduanyu3714 could promote PC cell proliferation, antiapoptosis, and GEM resistance via NF-κB signaling pathway, highlighting its potential role as a therapeutic target for PC.

KEYWORDS: {{ getKeywords(articleDetailText.words) }}